These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 16096518

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. The Treatment of Severe Childhood Aggression Study: 12 Weeks of Extended, Blinded Treatment in Clinical Responders.
    Findling RL, Townsend L, Brown NV, Arnold LE, Gadow KD, Kolko DJ, McNamara NK, Gary DS, Kaplin DB, Farmer CA, Kipp H, Williams C, Butter EM, Bukstein OG, Rice R, Buchan-Page K, Molina BS, Aman MG.
    J Child Adolesc Psychopharmacol; 2017 Feb; 27(1):52-65. PubMed ID: 28212067
    [Abstract] [Full Text] [Related]

  • 25. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia.
    Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R, Lee E, Lyons B, Grossman F.
    J Clin Psychiatry; 2003 Feb; 64(2):134-43. PubMed ID: 12633121
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. A double-blind pilot study of risperidone in the treatment of conduct disorder.
    Findling RL, McNamara NK, Branicky LA, Schluchter MD, Lemon E, Blumer JL.
    J Am Acad Child Adolesc Psychiatry; 2000 Apr; 39(4):509-16. PubMed ID: 10761354
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. The influence of risperidone on attentional functions in children and adolescents with attention-deficit/hyperactivity disorder and co-morbid disruptive behavior disorder.
    Günther T, Herpertz-Dahlmann B, Jolles J, Konrad K.
    J Child Adolesc Psychopharmacol; 2006 Dec; 16(6):725-35. PubMed ID: 17201616
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Co-morbid disruptive behavior disorder and aggression predict functional outcomes and differential response to risperidone versus divalproex in pharmacotherapy for pediatric bipolar disorder.
    West AE, Weinstein SM, Celio CI, Henry D, Pavuluri MN.
    J Child Adolesc Psychopharmacol; 2011 Dec; 21(6):545-53. PubMed ID: 22136096
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder: a placebo-controlled pilot study.
    Armenteros JL, Lewis JE, Davalos M.
    J Am Acad Child Adolesc Psychiatry; 2007 May; 46(5):558-565. PubMed ID: 17450046
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. The efficacy and tolerability of quetiapine versus divalproex for the treatment of impulsivity and reactive aggression in adolescents with co-occurring bipolar disorder and disruptive behavior disorder(s).
    Barzman DH, DelBello MP, Adler CM, Stanford KE, Strakowski SM.
    J Child Adolesc Psychopharmacol; 2006 Dec; 16(6):665-70. PubMed ID: 17201610
    [Abstract] [Full Text] [Related]

  • 40. Risperidone in children with disruptive behavior disorders and subaverage intelligence: a 1-year, open-label study of 504 patients.
    Croonenberghs J, Fegert JM, Findling RL, De Smedt G, Van Dongen S, Risperidone Disruptive Behavior Study Group.
    J Am Acad Child Adolesc Psychiatry; 2005 Jan; 44(1):64-72. PubMed ID: 15608545
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.